Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Ally Bridge Group (NY) LLC

Q1 2024 · 13F-HR

Ally Bridge Group (NY) LLCholdings as filed

Filed 2024-05-15 · accession 0000950123-24-005227

$179.9M
Reported value
22
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
09627Y1092655787DBLUEPRINT MEDICINES CORP$15.3M8.49%160,950CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$14.4M8.01%336,486CommonSOLE
156944100CGONCG ONCOLOGY INC$14.1M7.82%320,378CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$13.3M7.40%309,369CommonSOLE
925050106VRNAVERONA PHARMA PLC$11.9M6.59%736,738CommonSOLE
N5749R1002GHMERUS N V$11.5M6.41%255,928CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$9.7M5.41%159,486CommonSOLE
60255C885BRD1EURMIND MEDICINE MINDMED INC$9.4M5.23%1,001,452CommonSOLE
05337M104AVADEL PHARMACEUTICALS PLC$9.2M5.14%547,036CommonSOLE
374163103GERNGERON CORP$9.1M5.06%2,760,497CommonSOLE
471871202JSPRJASPER THERAPEUTICS INC$8.5M4.73%289,943CommonSOLE
50127T109KURAKURA ONCOLOGY INC$7.8M4.33%365,044CommonSOLE
457669307INSMINSMED INC$6.8M3.77%250,000CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$6.5M3.62%216,968CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$6.3M3.52%559,035CommonSOLE
55234L105LYRAGBPLYRA THERAPEUTICS INC$6.2M3.47%1,003,741CommonSOLE
54300N103LONGBOARD PHARMACEUTICALS IN$5.8M3.25%270,559CommonSOLE
75382E109RAPT THERAPEUTICS INC$3.8M2.10%420,000CommonSOLE
59045L106MERSANA THERAPEUTICS INC$3.6M2.00%801,437CommonSOLE
56854Q200MRNS*MARINUS PHARMACEUTICALS INC$3.6M1.98%394,773CommonSOLE
74346M406PMNEURPROMIS NEUROSCIENCES INC$2.0M1.13%1,059,582CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$1.0M0.56%725,951CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.